Key Points
SHLTN.SW stock falls 7.34% to CHF 1.01 amid negative earnings and weak fundamentals.
Company reports -0.76 CHF EPS with -26.24% net margin and negative operating cash flow.
Technical indicators show extreme oversold conditions with RSI 42.40 and CCI -235.28.
Meyka AI rates stock C+ with HOLD recommendation citing profitability concerns.
SHL Telemedicine Ltd. (SHLTN.SW) is trading lower in pre-market action on the SIX exchange today. The SHLTN.SW stock has declined 7.34% to CHF 1.01, marking a significant pullback from yesterday’s close of CHF 1.09. This Israeli telemedicine company develops personal ECG devices and remote health monitoring solutions. The stock is now trading near its 52-week low of CHF 0.66, down from a high of CHF 2.19. Trading volume has surged to 51,856 shares, more than triple the average daily volume of 14,084. We examine what’s driving this sharp decline and what it means for investors tracking this healthcare innovator.
Why SHLTN.SW Stock Is Falling Today
The SHLTN.SW stock decline reflects deeper operational challenges facing SHL Telemedicine. The company reported negative earnings per share of -0.76 CHF, with a negative PE ratio of -1.34, indicating ongoing losses. Operating margins turned negative at -9.30%, showing the company burns cash on core operations.
Meyka AI rates SHLTN.SW with a grade of C+, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s return on equity stands at -37.84%, reflecting shareholder value destruction. These grades are not guaranteed and we are not financial advisors.
Financial Metrics Signal Distress
SHL Telemedicine faces significant profitability headwinds across multiple metrics. The company’s net profit margin sits at -26.24%, meaning every sale generates losses. Free cash flow per share is negative at -0.13 CHF, indicating the business consumes rather than generates cash.
The debt-to-equity ratio of 0.30 remains manageable, but the company’s current ratio of 1.25 shows adequate short-term liquidity. However, with negative operating cash flow and mounting losses, cash reserves will deplete quickly. Revenue per share of 2.42 CHF cannot offset the operational burn rate, creating a sustainability crisis.
Market Sentiment and Technical Weakness
Technical indicators confirm bearish momentum in SHLTN.SW stock trading. The Relative Strength Index (RSI) sits at 42.40, approaching oversold territory. The Commodity Channel Index (CCI) reads -235.28, indicating extreme oversold conditions. Williams %R stands at -90.00, suggesting maximum selling pressure.
Average True Range (ATR) of 0.05 CHF shows volatility has compressed, yet the stock continues lower. The stock trades below its 50-day moving average of 1.06 CHF and well below its 200-day average of 1.17 CHF. Money Flow Index (MFI) at 32.22 signals weak institutional buying interest. Track SHLTN.SW on Meyka for real-time updates on this deteriorating technical picture.
Long-Term Performance Collapse
The SHLTN.SW stock has suffered catastrophic long-term losses that explain today’s weakness. Over the past three years, the stock has plummeted 88.47%, destroying investor capital. The five-year decline reaches 91.17%, while the ten-year loss totals 84.85%. Year-to-date performance shows a 13.98% decline, with one-year losses at 48.48%.
The company’s six-month performance of +41.96% represents a brief recovery that has now reversed sharply. Meyka AI’s forecast model projects monthly prices near 1.07 CHF and quarterly prices around 0.89 CHF, suggesting further downside risk. Forecasts are model-based projections and not guarantees. This extended underperformance reflects structural challenges in the telemedicine business model.
Final Thoughts
SHL Telemedicine’s SHLTN.SW stock decline reflects fundamental business deterioration rather than temporary market weakness. Negative earnings, collapsing margins, and negative cash flow create an unsustainable situation. The company’s C+ grade from Meyka AI and HOLD recommendation acknowledge these challenges. With the stock down 88% over three years and trading near 52-week lows, recovery appears distant. Investors should monitor quarterly earnings closely and watch for strategic pivots or partnerships that could stabilize operations. The telemedicine sector remains promising, but SHL Telemedicine must demonstrate a clear path to profitability to restore investor confidence.
FAQs
SHLTN.SW stock fell due to ongoing profitability challenges. The company reports negative earnings of -0.76 CHF per share and negative operating margins of -9.30%. Weak technical indicators and oversold conditions triggered selling pressure in pre-market trading.
Meyka AI rates SHLTN.SW with a C+ grade and HOLD recommendation. This grade evaluates S&P 500 benchmarks, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Yes, multiple indicators suggest oversold conditions. The RSI reads 42.40, CCI shows -235.28, and Williams %R stands at -90.00. However, oversold conditions don’t guarantee immediate recovery, especially with negative fundamentals.
Meyka AI’s forecast model projects monthly prices near 1.07 CHF and quarterly prices around 0.89 CHF. These are model-based projections and not guarantees. Current price of 1.01 CHF sits between these forecasts.
The C+ HOLD grade suggests caution. Negative cash flow, collapsing margins, and three-year losses of 88% indicate structural challenges. Investors should wait for evidence of profitability improvement before considering entry positions.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)